

chronic schizophrenia improving during pregnancy when estrogen levels are extremely high.

Methods: A double-blind, 28-day, placebo-controlled, adjunctive study was conducted comprising two groups of women of childbearing age. While one group of women received 100 mcg transdermal estradiol, the other group received transdermal placebo. The differences in psychopathology between the two groups were subsequently compared. Hormone, psychopathology and cognitive assessments were performed routinely throughout the 4-week trial period.

Results: Using the Positive and Negative Syndrome Scale (PANSS) rating scale, it was noted that women receiving 100 mcg estradiol improved significantly more in terms of their psychotic symptoms compared with women receiving placebo. Importantly, women who received estradiol improved with regard to positive, negative and general symptoms on the PANSS, in contrast to women on the placebo arm.

Conclusions: Estradiol appears to be a useful treatment for women with schizophrenia. We are furthering this exciting area of research by conducting a multisite ‘proof-of-concept’ study to determine whether estradiol can be used as an adjunctive treatment of psychotic symptoms in women with schizophrenia.

Using theories of delusion formation to explain abnormal thinking in patients with body dysmorphic disorder

I Labuschagne¹, D Castle², M Kyrios³, S Rossell¹

¹Mental Health Research Institute of Victoria; ²St Vincent’s Hospital, Melbourne; and ³Swinburne University, Melbourne, Australia

Background: Body dysmorphic disorder (BDD) is characterized by an overvalued or delusional belief of ‘imagined ugliness’. According to the literature, delusional beliefs have been explained by four alternative theories, which include faulty perceptions, theory of mind deficits, reasoning abnormalities and corruption of semantic memory. The current study examined whether these potential explanations are relevant to delusion formation in BDD.

Method: Preliminary data from 10 BDD patients and 10 matched healthy controls were analyzed. The clinical assessment involved questionnaires measuring self-esteem, self-ambivalence, delusional thinking and creative experiences. The cognitive test battery included visual affect perception, semantic memory for somatic concepts, cognitive inhibition associated with somatic and nonsomatic words, and language fluency.

Results: The results confirmed previous findings that patients with BDD are more delusional but additionally showed that delusional beliefs are exceedingly

distressing and preoccupying for these patients. Similarly, on a semantic memory task, patients with BDD showed greater acceptance of unusual ideas especially with regard to somatic compared with neutral information. On the fluency task, patients with BDD showed impaired semantic fluency but intact phonological fluency. Furthermore, patients with BDD were impaired in recognizing angry facial expressions, with no deficits on identifying other emotions.

Conclusions: These results have indicated the influence of delusional thinking on cognitive processing in BDD. They have suggested that delusional beliefs may be explained in terms of impaired semantic memory and faulty perception of angry information; these deficits in turn may explain the specificity of preoccupations in BDD.

One-year estimate of depot antipsychotic adherence and readmission in Victorian community mental health settings

T Lambert¹, A de Castella², A-n Ong³, J Kulkarni², B Singh⁴

¹OPEN, The University of Melbourne and ORYGEN Research Centre; ²Alfred Psychiatric Research Centre, The Alfred and Monash University; ³Northwestern Mental Health; and ⁴The University of Melbourne, Australia

Background: This study aimed to 1) to establish the actual or ‘found’ depot adherence rate in typical community psychiatric settings, 2) to describe the sociodemographic associations with depot adherence and 3) to investigate the relationship between the degree of depot adherence and admission rate to hospital.

Methods: Patients treated with depot antipsychotics were sampled from CCT settings in two AMHSs in urban Melbourne. Depot adherence was defined as patients receiving their injection ± 7 days from the due injection date. Sociodemographic data were acquired from relevant administrative databases.

Results: The study finds that there is a high mean adherence rate (93%) and the rate of complete adherence is 54%. Patients’ adherence was not related to gender, being subject to a CTO, being of NESB, long durations of illness or time on depot treatment. Twenty-eight per cent were admitted in the study year and admission was significantly inversely proportional to depot adherence. The risks of readmission increase significantly when patients are less than 85% adherent, having a relative risk of readmission of 2.63, and for those with less than 75% adherence, a relative risk of 4.32 ($P < 0.01$).

Conclusions: To our knowledge, this is the first study to report on the FDAR in community-treated patients.